In a transcriptome analysis of 83 cases of HER2-positive advanced GC treated with trastuzumab, amplifications were frequently seen in genes associated with the G1/S cell cycle checkpoint, such as CCNE1 (28.6%) and CDK6 (9.52%) [108]. This evidence concerns the gene ERBB2 and gastric cancer.